(19)

(11)

EP 3 253 739 A1

(12)

(43) Date of publication: 13.12.2017 Bulletin 2017/50 (21) Application number: 16746032.8 (22) Date of filing: 03.02.2016

(51) International Patent Classification (IPC):  C07D 239/94(2006.01) A61P 35/00(2006.01) C07D 403/12(2006.01) A61K 31/517(2006.01) C07D 401/12(2006.01) (86) International application number: PCT/CA2016/050094 (87) International publication number: WO 2016/123706 (11.08.2016 Gazette 2016/32)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: MA MD (30) Priority: 03.02.2015 US 201562111240 P (71) Applicant: Trillium Therapeutics Inc. Mississauga, Ontario L5L 1J9 (CA)	(72) Inventors: SLASSI, Abdelmalik Mississauga, Ontario L5M 7J7 (CA) DOVE, Peter Burlington, Ontario L7L 7L7 (CA) (74) Representative: HGF Limited  4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG Manchester M1 5WG (GB)